Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keishi-ka-shakuyaku-daio-to for Symptomatic Pneumatosis Cystoides
NCT04368663Recruiting
- Sponsor
- Showa Inan General Hospital
- Start
- May 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of keishi-ka-shakuyaku-daio-to in Pneumatosis cystoides intestinalis (PCI) (2 arms), sponsored by Showa Inan General Hospital. Primary endpoint: Change of computed tomography (CT) findings at 8 weeks. Started May 2020; status: recruiting.
02
Drugs
keishi-ka-shakuyaku-daio-to
03
Conditions
Pneumatosis cystoides intestinalis (PCI)
Beyond the preview
Go deeper on NCT04368663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04368663.